Previous 10 | Next 10 |
home / stock / sphdf / sphdf news
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, June 6 , 202 3 – Santhera Pharmaceuticals (SIX: SANN) ...
2023-06-01 14:08:53 ET Santhera Pharmaceuticals press release ( OTC:SPHDF ): FY GAAP EPS of -CHF1.17. Cash and cash equivalents of CHEF 1.35M For further details see: Santhera Pharmaceuticals GAAP EPS of -CHF1.17
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 31 , 202 3 – Santhera Pharmaceuticals (SIX: SANN) announces the publication of its Annual Report 2022 with fully audited results for the year ended December 31, ...
Pratteln, Switzerland, and Rockville, MD, USA , April 25 , 202 3 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce the successful completion of the mid-cycle review meeting by the U.S. Food and Drug Administrati...
Pratteln, Switzerland, March 2 , 202 3 – Santhera Pharmaceuticals (SIX: SANN) announces that it has submitted a marketing authorization application (MAA) to the UK Medicines and Healthcare p roducts Regulatory Agency (MHRA) for vamorolone for...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Funding intended to support Company through FDA decision on vamorolone in DMD Company forms Strategy C...
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, Febr uary 8 , 202 3 – Santhera Pharmaceuticals (SIX: SANN) announces that it has secured a final reimbursement agreement with the French a uthorities ...
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, January 10, 202 3 – Santhera Pharmaceuticals (SIX: SANN) announces that through a share exchange it will receive the equivalent of CHF 5 million Idorsia shares which Sant...
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, January 9, 2023 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the U.S. Food and Drug Administration (FDA) has accepted the ...
Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2022 Earnings Conference Call November 07, 2022, 08:30 ET Company Participants Dario Eklund - CEO Andrew Smith - CFO Shabir Hasham - Chief Medical Officer Conference Call Participants Bob Pooler - valuati...
News, Short Squeeze, Breakout and More Instantly...
Santhera Pharms Hldgs Ltd Company Name:
SPHDF Stock Symbol:
OTCMKTS Market:
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 28, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the publication of its Annual Report 2023 with fully audited results for the year ended December 31, 2023. Santhera’s Annual Report 2...
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full R...
Pratteln, Switzerland, March 27, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that the China National Medical Products Administration (NMPA) has accepted for priority review the new drug application (NDA) for vamorolone in Duchenne muscular dystrophy (DMD) which was submitted...